Ticker LaunchIPO · GRPH
LENZ Therapeutics, Inc.
Formerly Graphite Bio, Inc.
LENZ Therapeutics, Inc. (GRPH) priced its initial public offering on Jun 28, 2021 at $17.00 per share, raising $238M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $951.6M. Goodwin Procter advised the company and Cooley advised the underwriters.
At its 2021 IPO, Graphite Bio (now LENZ Therapeutics) was a clinical-stage gene editing company using targeted gene integration to develop therapies for serious diseases. Its lead program, GPH101, was in early clinical development.
- Status
- IPO
- Ticker
- GRPH
- Exchange
- Nasdaq Global Market
- Priced
- Jun 28, 2021
- IPO price
- $17.00
- Raised
- $238M
- Market cap at IPO price
- $951.6M
- First filed
- Jun 4, 2021
- Company counsel
- Goodwin Procter
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jun 4, 2021
- Latest amendment Jun 22, 2021
- Final prospectus (424B4) Jun 28, 2021
- All filings on EDGAR CIK 1815776
Other Biotech & pharma IPOs in 2021
- Jade Biosciences, Inc.AVTE · Jun 30, 2021
- Acurx Pharmaceuticals, Inc.ACXP · Jun 28, 2021
- GH Research PLCGHRS · Jun 28, 2021
- Bon Natural Life LtdBON · Jun 25, 2021 · $11M
- Elevation Oncology, Inc.ELEV · Jun 25, 2021
- Alpha Teknova, Inc.TKNO · Jun 25, 2021 · $96M